Monitoring of Serum Vancomycin Concentrations in Pediatric Patients with Normal Renal Function

Khotaei, Ghamar Taj; Jam, Sara; SeyedAlinaghi, SeyedAhmad; Motamed, Fatemeh; Nejat, Farideh; Ashtiani, Mohammad Taghi Haghi; Izadyar, Mina
April 2010
Acta Medica Iranica;2010, Vol. 48 Issue 2, p91
Academic Journal
Vancomycin is a a glycopeptide antibiotic with bacetiocidal effects on gram positive bacteria by interfering with cell wall synthesis. The necessity for monitoring of serum vancomycin concentrations(SVCs) has been recently noticed at many institutions because of concerns for its nephrotoxicity. We aimed to describe the SVCs monitoring in pediatric patients, in an effort to determine subtherapeutic or toxic levels. The medical records were reviewed for all patients older than 60 days of age admitted to the general or subspecialty services who received intravenous vancomycin at Children's Medical Hospital in Tehran, Iran between July 2003 and December 2005. Because pharmacokinetic parameters for children with cancer maybe different, this group was evaluated separately. During the study, 167 infants and children without cancer and 42 patients with cancer; aged between 3 months to 17.5 years were treated with vancomycin for various infections. In children without cancer, peak SVCs were in an adequate therapeutic range for 93% of patients(8-55 μg/ml). For children with cancer, peak SVCs was lower than 10 μg/ml (10%), and trough values were lower than 5 μg/ml (21%). In conclusion, according to the results of this research, due to different pharmacokinetics of vancomycin in cancerous patients, the monitoring of vancomycin plasma concentrations is necessary for the best therapeutic antibacterial activities with a fewer occurrence of serious adverse effects.


Related Articles

  • Surviving Childhood Cancer: The Impact on Life. Goldsby, Robert E.; Taggart, Denah R.; Ablin, Arthur R. // Pediatric Drugs;2006, Vol. 8 Issue 2, p71 

    With modern therapies, most children diagnosed with cancer are expected to reach adulthood. Therefore, there are large and ever-increasing numbers of children and young adults in our population who are survivors of childhood cancer. Many of the therapies responsible for improved cancer...

  • Vancomycin.  // Reactions Weekly;7/28/2012, Issue 1412, p44 

    The article describes the case of several patients who developed nephrotoxicity while receiving high-dose vancomycin.

  • Journal of Adolescent and Young Adult Oncology (JAYAO).  // Biomedical Market Newsletter;4/14/2012, Vol. 21, p1 

    The article informs that accurate measures are needed to assess the health of childhood cancer survivors.

  • Preparedness to Respond to the Ever-increasing Cancer Cases. Haileamlak, Abraham // Ethiopian Journal of Health Sciences;Oct2015, Vol. 25 Issue 4, p293 

    The article discusses issues related to treatment and diagnosis of cancer in children.

  • Cancer Survival Rates for Children Under Age 15 Years in Great Britain.  // JNCI: Journal of the National Cancer Institute;8/15/2001, Vol. 93 Issue 16, p1130 

    Presents a graph depicting the survival rate of children with cancer in Great Britain. Cancer cases commonly present in childhood; Risk of childhood cancer survivors of developing a second cancer later in life; Improvement on the data attributed on the development in treatment.

  • Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. Urien, Saik; Doz, François; Giraud, Carole; Rey, Elisabeth; Gentet, Jean-Claude; Chastagner, Pascal; Vassal, Gilles; Corradini, Nadège; Auvrignon, Anne; Leblond, Pierre; Rubie, Hervé; Treluyer, Jean-Marc // Cancer Chemotherapy & Pharmacology;Mar2011, Vol. 67 Issue 3, p597 

    Purpose: A randomized clinical trial examined whether dexamethasone administration prior to ondansetron followed by etoposide and carboplatin infusions, and single-nucleotide polymorphisms (SNPs) of CYP3A4, CYP3A5 and MDR1 genes could modify etoposide pharmacokinetics in pediatric patients....

  • Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration. Trame, Mirjam; Bartelink, Imke; Boos, Joachim; Boelens, Jaap; Hempel, Georg // Cancer Chemotherapy & Pharmacology;Nov2013, Vol. 72 Issue 5, p1149 

    Purpose: N, N-dimethylacetamide (DMA) is administered to children during high-dose chemotherapy as a solubilizer with the intravenous formulation of busulfan (Busilvex). DMA has shown liver toxicity in rats. However, little is known regarding its pharmacokinetics (PK) in humans. The aim of this...

  • Vancomycin. Marsot, Amélie; Boulamery, Audrey; Bruguerolle, Bernard; Simon, Nicolas // Clinical Pharmacokinetics;2012, Vol. 51 Issue 1, p1 

    Despite nearly five decades of clinical use, vancomycin has retained a significant and uncontested niche in the antibacterial arsenal because of its consistent activity against almost all Gram-positive bacteria. Nevertheless, major vancomycin toxicities have been reported in the literature - in...

  • Pharmacodynamic Characteristics of Nephrotoxicity Associated With Vancomycin Use in Children. Le, Jennifer; Ny, Pamela; Capparelli, Edmund; Lane, James; Ngu, Becky; Muus, Richard; Romanowski, Gale; Vo, Tiana; Bradley, John // Journal of the Pediatric Infectious Diseases Society;Dec2015, Vol. 4 Issue 4, pe109 

    Background. Limited studies incorporating population-based pharmacokinetic modeling have been conducted to determine pharmacodynamic indices associated with nephrotoxicity during vancomycin exposure in children. Methods. A retrospective cohort analysis was conducted from September 2003 to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics